Therapeutics. Medical search

Procedures concerned with the remedial treatment or prevention of diseases.

An advisory group composed primarily of staff physicians and the pharmacist which serves as the communication link between the medical staff and the pharmacy department.

The branch of pharmacology that deals directly with the effectiveness and safety of drugs in humans.

Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.

New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis.

Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease.

Substances that inhibit or prevent the proliferation of NEOPLASMS.

The process of finding chemicals for potential therapeutic use.

Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.

A cell line derived from cultured tumor cells.

Nanometer-sized particles that are nanoscale in three dimensions. They include nanocrystaline materials; NANOCAPSULES; METAL NANOPARTICLES; DENDRIMERS, and QUANTUM DOTS. The uses of nanoparticles include DRUG DELIVERY SYSTEMS and cancer targeting and imaging.

The branch of medicine concerned with the application of NANOTECHNOLOGY to the prevention and treatment of disease. It involves the monitoring, repair, construction, and control of human biological systems at the molecular level, using engineered nanodevices and NANOSTRUCTURES. (From Freitas Jr., Nanomedicine, vol 1, 1999).

The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.

Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.

Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers.

Large collections of small molecules (molecular weight about 600 or less), of similar or diverse nature which are used for high-throughput screening analysis of the gene function, protein interaction, cellular processing, biochemical pathways, or other chemical interactions.

Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.

Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.

Nucleotide sequences, generated by iterative rounds of SELEX APTAMER TECHNIQUE, that bind to a target molecule specifically and with high affinity.

Drugs which have received FDA approval for human testing but have yet to be approved for commercial marketing. This includes drugs used for treatment while they still are undergoing clinical trials (Treatment IND). The main heading includes drugs under investigation in foreign countries.

Procedures by which protein structure and function are changed or created in vitro by altering existing or synthesizing new structural genes that direct the synthesis of proteins with sought-after properties. Such procedures may include the design of MOLECULAR MODELS of proteins using COMPUTER GRAPHICS or other molecular modeling techniques; site-specific mutagenesis (MUTAGENESIS, SITE-SPECIFIC) of existing genes; and DIRECTED MOLECULAR EVOLUTION techniques to create new genes.

Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures.

Antibodies produced by a single clone of cells.

All of the processes involved in increasing CELL NUMBER including CELL DIVISION.

A gene silencing phenomenon whereby specific dsRNAs (RNA, DOUBLE-STRANDED) trigger the degradation of homologous mRNA (RNA, MESSENGER). The specific dsRNAs are processed into SMALL INTERFERING RNA (siRNA) which serves as a guide for cleavage of the homologous mRNA in the RNA-INDUCED SILENCING COMPLEX. DNA METHYLATION may also be triggered during this process.

Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment.

The use of DRUGS to treat a DISEASE or its symptoms. One example is the use of ANTINEOPLASTIC AGENTS to treat CANCER.

Rapid methods of measuring the effects of an agent in a biological or chemical assay. The assay usually involves some form of automation or a way to conduct multiple assays at the same time using sample arrays.

One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.

In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.

Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay.

Therapeutic approach tailoring therapy for genetically defined subgroups of patients.

Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.

The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.

Compounds formed by the joining of smaller, usually repeating, units linked by covalent bonds. These compounds often form large macromolecules (e.g., BIOPOLYMERS; PLASTICS).

Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.

Established cell cultures that have the potential to propagate indefinitely.

Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.

Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.

The study of the physical and chemical properties of a drug and its dosage form as related to the onset, duration, and intensity of its action.

The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture.

The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds.

The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.

The development and use of techniques to study physical phenomena and construct structures in the nanoscale size range or smaller.

Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize.

Transmission of energy or mass by a medium involving movement of the medium itself. The circulatory movement that occurs in a fluid at a nonuniform temperature owing to the variation of its density and the action of gravity. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed; Webster, 10th ed)

Agents that inhibit PROTEIN KINASES.

A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "nonspecific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p252)

The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.

Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.

The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups.

The application of engineering principles and methods to living organisms or biological systems.

Peptides that have the ability to enter cells by crossing the plasma membrane directly, or through uptake by the endocytotic pathway.

The application of discoveries generated by laboratory research and preclinical studies to the development of clinical trials and studies in humans. A second area of translational research concerns enhancing the adoption of best practices.

Body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful. Alteration of biologic function at the molecular level (i.e., GENETIC ENGINEERING) is a central focus; laboratory methods used include TRANSFECTION and CLONING technologies, sequence and structure analysis algorithms, computer databases, and gene and protein structure function analysis and prediction.

Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.

Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.

A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed)

Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.

The level of protein structure in which combinations of secondary protein structures (alpha helices, beta sheets, loop regions, and motifs) pack together to form folded shapes called domains. Disulfide bridges between cysteines in two different parts of the polypeptide chain along with other interactions between the chains play a role in the formation and stabilization of tertiary structure. Small proteins usually consist of only one domain but larger proteins may contain a number of domains connected by segments of polypeptide chain which lack regular secondary structure.

Small double-stranded, non-protein coding RNAs, 21-25 nucleotides in length generated from single-stranded microRNA gene transcripts by the same RIBONUCLEASE III, Dicer, that produces small interfering RNAs (RNA, SMALL INTERFERING). They become part of the RNA-INDUCED SILENCING COMPLEX and repress the translation (TRANSLATION, GENETIC) of target RNA by binding to homologous 3'UTR region as an imperfect match. The small temporal RNAs (stRNAs), let-7 and lin-4, from C. elegans, are the first 2 miRNAs discovered, and are from a class of miRNAs involved in developmental timing.

Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.

Works about lists of drugs or collections of recipes, formulas, and prescriptions for the compounding of medicinal preparations. Formularies differ from PHARMACOPOEIAS in that they are less complete, lacking full descriptions of the drugs, their formulations, analytic composition, chemical properties, etc. In hospitals, formularies list all drugs commonly stocked in the hospital pharmacy.

The application of scientific knowledge or technology to pharmacy and the pharmaceutical industry. It includes methods, techniques, and instrumentation in the manufacture, preparation, compounding, dispensing, packaging, and storing of drugs and other preparations used in diagnostic and determinative procedures, and in the treatment of patients.

A collection of cloned peptides, or chemically synthesized peptides, frequently consisting of all possible combinations of amino acids making up an n-amino acid peptide.

High molecular weight polymers containing a mixture of purine and pyrimidine nucleotides chained together by ribose or deoxyribose linkages.

Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.

Treatment of diseases with biological materials or biological response modifiers, such as the use of GENES; CELLS; TISSUES; organs; SERUM; VACCINES; and humoral agents.

Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.

The relationship between the dose of an administered drug and the response of the organism to the drug.

Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.

Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.

Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.

Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.

A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)

Treatments which are undergoing clinical trials or for which there is insufficient evidence to determine their effects on health outcomes; coverage for such treatments is often denied by health insurers.

Materials which have structured components with at least one dimension in the range of 1 to 100 nanometers. These include NANOCOMPOSITES; NANOPARTICLES; NANOTUBES; and NANOWIRES.

Therapies that involve the TRANSPLANTATION of CELLS or TISSUES developed for the purpose of restoring the function of diseased or dysfunctional cells or tissues.

Polymers made up of a few (2-20) nucleotides. In molecular genetics, they refer to a short sequence synthesized to match a region where a mutation is known to occur, and then used as a probe (OLIGONUCLEOTIDE PROBES). (Dorland, 28th ed)

A cell line generated from human embryonic kidney cells that were transformed with human adenovirus type 5.

A form of antibodies consisting only of the variable regions of the heavy and light chains (FV FRAGMENTS), connected by a small linker peptide. They are less immunogenic than complete immunoglobulin and thus have potential therapeutic use.

Measurable biological parameters that serve for drug development, safety and dosing (DRUG MONITORING).

Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.

Tailored macromolecules harboring covalently-bound biologically active modules that target specific tissues and cells. The active modules or functional groups can include drugs, prodrugs, antibodies, and oligonucleotides, which can act synergistically and be multitargeting.

Any visual display of structural or functional patterns of organs or tissues for diagnostic evaluation. It includes measuring physiologic and metabolic responses to physical and chemical stimuli, as well as ultramicroscopy.

Antiserum given therapeutically in BOTULISM.

The study of the origin, nature, properties, and actions of drugs and their effects on living organisms.

DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.

A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.

The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)

Proteins prepared by recombinant DNA technology.

The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.

Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.

Tumors or cancer of the human BREAST.

The deliberate and methodical practice of finding new applications for existing drugs.

Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.

A branch of genetics which deals with the genetic variability in individual responses to drugs and drug metabolism (BIOTRANSFORMATION).

The field of medicine concerned with understanding the biochemical basis of health and disease and involved in developing diagnostic and therapeutic methods that utilize MOLECULAR BIOLOGY techniques.

Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.

Tree-like, highly branched, polymeric compounds. They grow three-dimensionally by the addition of shells of branched molecules to a central core. The overall globular shape and presence of cavities gives potential as drug carriers and CONTRAST AGENTS.

The introduction of functional (usually cloned) GENES into cells. A variety of techniques and naturally occurring processes are used for the gene transfer such as cell hybridization, LIPOSOMES or microcell-mediated gene transfer, ELECTROPORATION, chromosome-mediated gene transfer, TRANSFECTION, and GENETIC TRANSDUCTION. Gene transfer may result in genetically transformed cells and individual organisms.

Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.

A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein.

A field of medicine concerned with developing and using strategies aimed at repair or replacement of damaged, diseased, or metabolically deficient organs, tissues, and cells via TISSUE ENGINEERING; CELL TRANSPLANTATION; and ARTIFICIAL ORGANS and BIOARTIFICIAL ORGANS and tissues.

The parts of a macromolecule that directly participate in its specific combination with another molecule.

Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation.

The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.

Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.

Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS.

A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.

The use of molecularly targeted imaging probes to localize and/or monitor biochemical and cellular processes via various imaging modalities that include RADIONUCLIDE IMAGING; ULTRASONOGRAPHY; MAGNETIC RESONANCE IMAGING; FLUORESCENCE IMAGING; and MICROSCOPY.

Infections with viruses of the family FILOVIRIDAE. The infections in humans consist of a variety of clinically similar viral hemorrhagic fevers but the natural reservoir host is unknown.

Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).

Specialized non-fenestrated tightly-joined ENDOTHELIAL CELLS with TIGHT JUNCTIONS that form a transport barrier for certain substances between the cerebral capillaries and the BRAIN tissue.

Interruption or suppression of the expression of a gene at transcriptional or translational levels.

The artificial induction of GENE SILENCING by the use of RNA INTERFERENCE to reduce the expression of a specific gene. It includes the use of DOUBLE-STRANDED RNA, such as SMALL INTERFERING RNA and RNA containing HAIRPIN LOOP SEQUENCE, and ANTI-SENSE OLIGONUCLEOTIDES.

Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins.

That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.

Dosage forms of a drug that act over a period of time by controlled-release processes or technology.

Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.

The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.

Peptides generated from AMYLOID BETA-PEPTIDES PRECURSOR. An amyloid fibrillar form of these peptides is the major component of amyloid plaques found in individuals with Alzheimer's disease and in aged individuals with trisomy 21 (DOWN SYNDROME). The peptide is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue.

A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.

Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.

Minute infectious agents whose genomes are composed of DNA or RNA, but not both. They are characterized by a lack of independent metabolism and the inability to replicate outside living host cells.

Societies whose membership is limited to pharmacists.

The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain).

RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.

Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.

The ability of a protein to retain its structural conformation or its activity when subjected to physical or chemical manipulations.

A genus in the family FILOVIRIDAE consisting of several distinct species of Ebolavirus, each containing separate strains. These viruses cause outbreaks of a contagious, hemorrhagic disease (HEMORRHAGIC FEVER, EBOLA) in humans, usually with high mortality.

Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.

Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.

The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.

Elements of limited time intervals, contributing to particular results or situations.

Experimental transplantation of neoplasms in laboratory animals for research purposes.

Formal instruction, learning, or training in the preparation, dispensing, and proper utilization of drugs in the field of medicine.

Transplantation between animals of different species.

Directed modification of the gene complement of a living organism by such techniques as altering the DNA, substituting genetic material by means of a virus, transplanting whole nuclei, transplanting cell hybrids, etc.

Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use.

Tumors or cancer of the PROSTATE.

Agents that have a damaging effect on the HEART. Such damage can occur from ALKYLATING AGENTS; FREE RADICALS; or metabolites from OXIDATIVE STRESS and in some cases is countered by CARDIOTONIC AGENTS. Induction of LONG QT SYNDROME or TORSADES DE POINTES has been the reason for viewing some drugs as cardiotoxins.

The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle.

Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.

A SMN complex protein that is closely-related to SURVIVAL OF MOTOR NEURON 1 PROTEIN. In humans, the protein is encoded by an often duplicated gene found near the inversion centromere of a large inverted region of CHROMOSOME 5.

Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.

Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.

Books used in the study of a subject that contain a systematic presentation of the principles and vocabulary of a subject.

Use of attenuated VIRUSES as ANTINEOPLASTIC AGENTS to selectively kill CANCER cells.

Substances that reduce or suppress INFLAMMATION.

Biologically active substances whose activities affect or play a role in the functioning of the immune system.

BENZOIC ACID amides.

Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.

Alteration of the immune system or of an immune response by agents that activate or suppress its function. This can include IMMUNIZATION or administration of immunomodulatory drugs. Immunomodulation can also encompass non-therapeutic alteration of the immune system effected by endogenous or exogenous substances.

Semisynthetic conjugates of various toxic molecules, including RADIOACTIVE ISOTOPES and bacterial or plant toxins, with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; and ANTIGENS. The antitumor or antiviral immune substance carries the toxin to the tumor or infected cell where the toxin exerts its poisonous effect.

A subspecialty of internal medicine concerned with the study of neoplasms.

A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.

Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.

The largest family of cell surface receptors involved in SIGNAL TRANSDUCTION. They share a common structure and signal through HETEROTRIMERIC G-PROTEINS.

The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety.

The entering of cells by viruses following VIRUS ATTACHMENT. This is achieved by ENDOCYTOSIS, by direct MEMBRANE FUSION of the viral membrane with the CELL MEMBRANE, or by translocation of the whole virus across the cell membrane.

Tumor-selective, replication competent VIRUSES that have antineoplastic effects. This is achieved by producing cytotoxicity-enhancing proteins and/or eliciting an antitumor immune response. They are genetically engineered so that they can replicate in CANCER cells but not in normal cells, and are used in ONCOLYTIC VIROTHERAPY.

A technology, in which sets of reactions for solution or solid-phase synthesis, is used to create molecular libraries for analysis of compounds on a large scale.

A biosensing technique in which biomolecules capable of binding to specific analytes or ligands are first immobilized on one side of a metallic film. Light is then focused on the opposite side of the film to excite the surface plasmons, that is, the oscillations of free electrons propagating along the film's surface. The refractive index of light reflecting off this surface is measured. When the immobilized biomolecules are bound by their ligands, an alteration in surface plasmons on the opposite side of the film is created which is directly proportional to the change in bound, or adsorbed, mass. Binding is measured by changes in the refractive index. The technique is used to study biomolecular interactions, such as antigen-antibody binding.

The systematic study of the complete DNA sequences (GENOME) of organisms.

Compounds that inhibit the function or proteolytic action of the PROTEASOME.

The action of a drug in promoting or enhancing the effectiveness of another drug.

A method of generating a large library of randomized nucleotides and selecting NUCLEOTIDE APTAMERS by iterative rounds of in vitro selection. A modified procedure substitutes AMINO ACIDS in place of NUCLEOTIDES to make PEPTIDE APTAMERS.

The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.

Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein.

Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.

The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for VIRUS CULTIVATION and antitumor drug screening assays.

Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.

Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.

Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS.

Non-human animals, selected because of specific characteristics, for use in experimental research, teaching, or testing.

A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.

Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.

Histochemical localization of immunoreactive substances using labeled antibodies as reagents.

A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS.

The removal of a consumer product from the market place. The reason for the removal can be due a variety of causes, including the discovery of a manufacturing defect, a safety issue with the product's use, or marketing decisions.

A strain of non-obese diabetic mice developed in Japan that has been widely studied as a model for T-cell-dependent autoimmune insulin-dependent diabetes mellitus in which insulitis is a major histopathologic feature, and in which genetic susceptibility is strongly MHC-linked.

A genus of the family Muridae consisting of eleven species. C. migratorius, the grey or Armenian hamster, and C. griseus, the Chinese hamster, are the two species used in biomedical research.

A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.

A species of CERCOPITHECUS containing three subspecies: C. tantalus, C. pygerythrus, and C. sabeus. They are found in the forests and savannah of Africa. The African green monkey (C. pygerythrus) is the natural host of SIMIAN IMMUNODEFICIENCY VIRUS and is used in AIDS research.

Strongly cationic polymer that binds to certain proteins; used as a marker in immunology, to precipitate and purify enzymes and lipids. Synonyms: aziridine polymer; Epamine; Epomine; ethylenimine polymer; Montrek; PEI; Polymin(e).

The termination of the cell's ability to carry out vital functions such as metabolism, growth, reproduction, responsiveness, and adaptability.

Relating to the size of solids.

Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.

Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.

Compounds that are designed to mimic the 3D structure of a natural peptide or protein.

Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.

Synthetic or natural materials, other than DRUGS, that are used to replace or repair any body TISSUES or bodily function.

A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.

The rate dynamics in chemical or physical systems.

The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.

R(1/180)

esearch note: does cost recovery for curative care affect preventive care utilization? (+info)

Issues in the measurement of satisfaction with treatment. (2/180)

Patients satisfaction with treatments is a growing area of research that has tremendous potential to provide outcome measures for clinical trials and disease management programs. It also has applications in marketing and product development, especially for the treatment of chronic diseases. The objective of this review is to demonstrate that treatment satisfaction is a distinct area of research that has produced some important initial results. We define treatment satisfaction and provide a conceptual framework that clarifies the role of treatment expectations, preferences, and satisfaction in the context of healthcare in general. Nineteen articles were selected from more than 1,400 abstracts and were reviewed for the following information: (1) topics covered; (2) method used to design the measure; (3) descriptive statistics; (4) assessment with respect to the attributes in the Instrument Review Criteria of the Medical Outcome Trust's Scientific Advisory Committee; and (5) covariates. We conclude that some important initial results about treatment satisfaction have been obtained, but that much work remains to be performed. We recommend that future research devote more attention to qualitative research with patients, assessment of the measures, and the covariates presented in the conceptual model. We also recommend that decision makers insist on measures that meet these criteria. (+info)

Impact of electronic imaging on clinician behavior in the urgent care setting. (3/180)

Although it is intuitively valuable that more expedient delivery of radiographic images and reports to clinicians would improve patient care, it is important to document these outcomes to validate further advances in these areas. We evaluated the care of 215 patients seen at a walk-in clinic to determine what benefit digital imaging is to the patient. Cohorts consisted of all patients for whom specified radiology examinations were ordered during a 7-day period. The first cohort was recruited when analog films were used. The second cohort received examinations performed with computed radiography (CR) acquisition and computer display, which had been in use for 2 years. Patients were categorized as to the type of study they received, as well as whether a staff radiologist was immediately available to read the study. Clinical behavior was characterized by outcome measures of time to final diagnosis, time to final treatment, and need for follow-up. Our analysis demonstrated a reduction in time to final diagnosis that was better appreciated during the times when a staff radiologist was not immediately available. It also suggested that greater time reductions were seen for patients who received extremity examinations than those who received chest, sinus, or rib films. These data suggest that digital imaging is a useful tool to improve clinical outcome of patients seen in the acute care setting. (+info)

Did Osler suffer from "paranoia antitherapeuticum baltimorensis"? A comparative content analysis of The Principles and Practice of Medicine and Harrison's Principles of Internal Medicine, 11th edition. (4/180)

One of the most important legacies of Sir William Osler was his textbook The Principles and Practice of Medicine. A common criticism of the book when it was first published was its deficiency in the area of therapeutics. In this article, the 1st edition of The Principles and Practice of Medicine is compared with the 11th edition of Harrison's Principles of Internal Medicine. The analysis focuses on the treatment recommendations for 4 conditions that were covered in both books (diabetes mellitus, ischemic heart disease, pneumonia and typhoid fever). Osler's textbook dealt with typhoid fever and pneumonia at greater length, whereas Harrison's placed more emphasis on diabetes mellitus and ischemic heart disease. Notwithstanding Osler's reputation as a therapeutic nihilist, the 2 books devoted equivalent space to treatment (in terms of proportion of total sentences for the conditions). For all conditions except ischemic heart disease, Osler concentrated on general measures and symptomatic care. Throughout Osler's textbook numerous negative comments are made about the medicinal treatment of various conditions. A more accurate statement about Osler's therapeutic approach was that he was a "medicinal nihilist." His demand for proof of efficacy before use of a medication remains relevant. (+info)

Restricted natural language processing for case simulation tools. (5/180)

For Interactive Patient II, a multimedia case simulation designed to improve history-taking skills, we created a new natural language interface called GRASP (General Recognition and Analysis of Sentences and Phrases) that allows students to interact with the program at a higher level of realism. Requirements included the ability to handle ambiguous word senses and to match user questions/queries to unique Canonical Phrases, which are used to identify case findings in our knowledge database. In a simulation of fifty user queries, some of which contained ambiguous words, this tool was 96% accurate in identifying concepts. (+info)

Detailed diagnoses and procedures, National Hospital Discharge Survey, 1997. (6/180)

OBJECTIVES: This report presents national estimates of the use of non-Federal short-stay hospitals in the United States during 1997. Estimates of first-listed diagnoses, all-listed diagnoses, days of care for first-listed diagnoses, and all-listed procedures are shown by sex and age of patient and geographic region of hospital. METHODS: The estimates are based on data collected through the National Hospital Discharge Survey for 1997. The survey has been conducted annually by the National Center for Health Statistics since 1965. In 1997 data were collected for approximately 300,000 discharges from 474 non-Federal short-stay hospitals. Diagnoses and procedures are presented according to their code number in the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). (+info)

A comparison of observational studies and randomized, controlled trials. (7/180)

BACKGROUND: For many years it has been claimed that observational studies find stronger treatment effects than randomized, controlled trials. We compared the results of observational studies with those of randomized, controlled trials. METHODS: We searched the Abridged Index Medicus and Cochrane data bases to identify observational studies reported between 1985 and 1998 that compared two or more treatments or interventions for the same condition. We then searched the Medline and Cochrane data bases to identify all the randomized, controlled trials and observational studies comparing the same treatments for these conditions. For each treatment, the magnitudes of the effects in the various observational studies were combined by the Mantel-Haenszel or weighted analysis-of-variance procedure and then compared with the combined magnitude of the effects in the randomized, controlled trials that evaluated the same treatment. RESULTS: There were 136 reports about 19 diverse treatments, such as calcium-channel-blocker therapy for coronary artery disease, appendectomy, and interventions for subfertility. In most cases, the estimates of the treatment effects from observational studies and randomized, controlled trials were similar. In only 2 of the 19 analyses of treatment effects did the combined magnitude of the effect in observational studies lie outside the 95 percent confidence interval for the combined magnitude in the randomized, controlled trials. CONCLUSIONS: We found little evidence that estimates of treatment effects in observational studies reported after 1984 are either consistently larger than or qualitatively different from those obtained in randomized, controlled trials. (+info)

Randomized, controlled trials, observational studies, and the hierarchy of research designs. (8/180)

BACKGROUND: In the hierarchy of research designs, the results of randomized, controlled trials are considered to be evidence of the highest grade, whereas observational studies are viewed as having less validity because they reportedly overestimate treatment effects. We used published meta-analyses to identify randomized clinical trials and observational studies that examined the same clinical topics. We then compared the results of the original reports according to the type of research design. METHODS: A search of the Medline data base for articles published in five major medical journals from 1991 to 1995 identified meta-analyses of randomized, controlled trials and meta-analyses of either cohort or case-control studies that assessed the same intervention. For each of five topics, summary estimates and 95 percent confidence intervals were calculated on the basis of data from the individual randomized, controlled trials and the individual observational studies. RESULTS: For the five clinical topics and 99 reports evaluated, the average results of the observational studies were remarkably similar to those of the randomized, controlled trials. For example, analysis of 13 randomized, controlled trials of the effectiveness of bacille Calmette-Guerin vaccine in preventing active tuberculosis yielded a relative risk of 0.49 (95 percent confidence interval, 0.34 to 0.70) among vaccinated patients, as compared with an odds ratio of 0.50 (95 percent confidence interval, 0.39 to 0.65) from 10 case-control studies. In addition, the range of the point estimates for the effect of vaccination was wider for the randomized, controlled trials (0.20 to 1.56) than for the observational studies (0.17 to 0.84). CONCLUSIONS: The results of well-designed observational studies (with either a cohort or a case-control design) do not systematically overestimate the magnitude of the effects of treatment as compared with those in randomized, controlled trials on the same topic. (+info)

Beckley Canopy Therapeutics[edit]. News reports in 2018-2019 indicated that the Foundation had been retained by the Canadian ... "Beckley Canopy Therapeutics raises £7.4m for cannabis R&D". PharmaForum. 4 December 2018. Retrieved 2 April 2019. As a new ... Beckley Canopy Therapeutics, based in Oxford, England has raised £7.4 million for the purposes of cannabinoid research and drug ... The two formed Beckley Canopy Therapeutics in Oxford, to raise funds from investors for cannabinoid research and drug ...

https://en.wikipedia.org/wiki/Amanda_Feilding

Therapeutics[edit]. Dr. Anstie was a skilful physician, an eager investigator, and a vigorous writer. Literary work connected ... In therapeutics he began with investigating the action of alcohol on the body in health and disease; and in this he was a pupil ... His activity was mainly directed in three lines-in the advancement of therapeutics, in questions of public health, and in the ... has done much to invigorate the study of therapeutics in the UK, were of Anstie's creation.[1] ...

https://en.wikipedia.org/wiki/Francis_E._Anstie

Therapeutics[edit]. Major diseases where altering capillary formation could be helpful include conditions where there is ...

https://en.wikipedia.org/wiki/Capillaries

Therapeutics[edit]. PD-1[edit]. Pembrolizumab (formerly MK-3475 or lambrolizumab, Keytruda) was developed by Merck and first ...

https://en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors

Harnessing evolution in therapeutics[edit]. Cancer drugs and therapies commonly used today are evolutionary inert and represent ... 6 Harnessing evolution in therapeutics *6.1 Anoxic bacteria *6.1.1 Possible limitations ...

https://en.wikipedia.org/wiki/Somatic_evolution_in_cancer

"Pharmacology & Therapeutics. 119 (1): 44-54. doi:10.1016/j.pharmthera.2008.04.005. PMC 2581864 . PMID 18579210.. ... Anticancer therapeutics[edit]. Intracellular heat shock proteins are highly expressed in cancerous cells and are essential to ...

https://en.wikipedia.org/wiki/Heat_shock_protein

Therapeutics targeting cancer EMT[edit]. Many studies have proposed that induction of EMT is the primary mechanism by which ... Antagomirs and microRNA mimics have gained interest as a potential source of therapeutics to target EMT induced metastasis in ... Rupaimoole, Rajesha; Slack, Frank J. (March 2017). "MicroRNA therapeutics: towards a new era for the management of cancer and ... "MicroRNA therapeutics: towards a new era for the management of cancer and other diseases". Nature Reviews Drug Discovery. 16 ...

https://en.wikipedia.org/wiki/Epithelial–mesenchymal_transition

Therapeutics[edit]. The process of neurodegeneration is not well understood, so the diseases that stem from it have, as yet, no ...

https://en.wikipedia.org/wiki/Neurodegenerative

Leader, Benjamin; Baca, Qentin J.; Golan, David E. (January 2008). "Protein therapeutics: a summary and pharmacological ... has developed a method to produce therapeutics in cultured transgenic carrot and tobacco cells.[65] Protalix and its partner, ...

https://en.wikipedia.org/wiki/Transgenic_animal

Therapeutics is the field, more commonly referenced in earlier periods of history, of the various remedies that can be used to ... "therapeutics (medicine)". Britannica Online Encyclopedia. Archived from the original on 18 December 2007. Retrieved 21 Apr 2012 ... Clinical pharmacology is concerned with how systems of therapeutics interact with patients. ...

https://en.wikipedia.org/wiki/Medical

Hosie AM, Wilkins ME, Smart TG (Oct 2007). "Neurosteroid binding sites on GABA(A) receptors". Pharmacology & Therapeutics. 116 ... The Journal of Pharmacology and Experimental Therapeutics. 300 (1): 2-8. doi:10.1124/jpet.300.1.2. PMID 11752090.. ... Therapeutics. 116 (1): 20-34. doi:10.1016/j.pharmthera.2007.03.007. PMID 17531325.. ...

https://en.wikipedia.org/wiki/GABAA_receptor_positive_allosteric_modulator

"Pharmacology & Therapeutics. 113 (3): 523-36. doi:10.1016/j.pharmthera.2006.11.006. PMC 2151919. PMID 17303246.. ... The Journal of Pharmacology and Experimental Therapeutics. 314 (2): 561-7. doi:10.1124/jpet.105.084947. PMID 15908513.. .mw- ...

https://en.wikipedia.org/wiki/ICI-118,551

Pharmacology & Therapeutics. 149: 150-90. doi:10.1016/j.pharmthera.2014.12.004. PMC 4380664. PMID 25550231.. ... Tam SW, Worcel M, Wyllie M (2001). "Yohimbine: a clinical review". Pharmacology and Therapeutics. 91 (3): 239. doi:10.1016/ ... 2013). Veterinary Pharmacology and Therapeutics (9 ed.). John Wiley & Sons. p. 353. ISBN 978-1118685907. .. ... Bosker G (1995). Emergency Medicine Therapeutics (2 ed.). Mosby, Incorporated. p. 342. ISBN 978-0815109921. .. ...

https://en.wikipedia.org/wiki/Yohimbine

Journal of Clinical Pharmacy and Therapeutics. 37 (2): 204-11. doi:10.1111/j.1365-2710.2011.01285.x. PMID 21740451. S2CID ... Therapeutics. 130 (2): 114-43. doi:10.1016/j.pharmthera.2010.12.008. PMID 21276815.. ...

https://en.wikipedia.org/wiki/COPD

"Pharmacology & Therapeutics. 126 (2): 119-45. doi:10.1016/j.pharmthera.2010.01.003. PMC 2854323. PMID 20153367.. ...

https://en.wikipedia.org/wiki/Orgotein

"Therapeutics and Clinical Risk Management. 4 (5): 1035-46. doi:10.2147/TCRM.S3343. PMC 2621406. PMID 19209284.. ... "Clinical Therapeutics. 25 (10): 2506-38. CiteSeerX 10.1.1.451.9407. doi:10.1016/S0149-2918(03)80314-4. PMID 14667954.. ... Clinical Pharmacology and Therapeutics. 42 (5): 535-41. doi:10.1038/clpt.1987.193. PMID 3677542.. ... "Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and ...

https://en.wikipedia.org/wiki/Lamotrigine

Pharmacology & Therapeutics. 140 (1): 34-52. doi:10.1016/j.pharmthera.2013.05.010. PMID 23711791.. ...

https://en.wikipedia.org/wiki/Epigenetics_of_neurodegenerative_diseases

"Pharmacology & Therapeutics. 124 (2): 195-206. doi:10.1016/j.pharmthera.2009.07.001. PMC 2785038. PMID 19619582.. ...

https://en.wikipedia.org/wiki/Donepezil

DOM-USA-5 Study Group". Clinical Therapeutics. 20 (3): 438-53. doi:10.1016/S0149-2918(98)80054-4. PMID 9663360.. ...

https://en.wikipedia.org/wiki/Domperidone

Therapeutics. 114 (2): 208-21. doi:10.1016/j.pharmthera.2007.02.004. PMID 17408751.. ...

https://en.wikipedia.org/wiki/Adenosine_receptor

The Journal of Pharmacology and Experimental Therapeutics. 318 (2): 657-65. doi:10.1124/jpet.106.103382. PMID 16675639.. ... 2006). Goodman & Gilman's: The Pharmacological Basis of Therapeutics (11 ed.). New York: McGraw-Hill.. CS1 maint: Uses editors ... Gutierrez MA, Stimmel GL, Aiso JY (August 2003). "Venlafaxine: a 2003 update". Clinical Therapeutics. 25 (8): 2138-54. doi: ... The Journal of Pharmacology and Experimental Therapeutics. 318 (2): 657-65. doi:10.1124/jpet.106.103382. PMID 16675639.. ...

https://en.wikipedia.org/wiki/Serotonin-norepinephrine_reuptake_inhibitor

Lipton SA (October 2007). "Pathologically activated therapeutics for neuroprotection". Nature Reviews. Neuroscience. 8 (10): ...

https://en.wikipedia.org/wiki/NMDA_receptor

Initially, the targeted therapeutics were supposed to be solely selective for one protein. Now it is clear that there is often ... Allen TM (Oct 2002). "Ligand-targeted therapeutics in anticancer therapy". Nature Reviews. Cancer. 2 (10): 750-63. PMID ... Teicher BA, Chari RV (Oct 2011). "Antibody conjugate therapeutics: challenges and potential". Clinical Cancer Research. 17 (20 ...

https://en.wikipedia.org/wiki/Chemotherapeutics

Clinical Therapeutics. 31 (1): 213-219. doi:10.1016/j.clinthera.2009.01.006. PMID 19243719.. ... Clinical Therapeutics. 28 (8): 1217-1224. doi:10.1016/j.clinthera.2006.07.009. PMID 16982299.. ... and participating in formulary development through Pharmacy and Therapeutics committees. The formulary system's effectiveness ...

https://en.wikipedia.org/wiki/Prescription_drug_prices_in_the_United_States

Havsteen, Bent H (November-December 2002). Pharmacology & Therapeutics. pp. 67-202.. *^ Vukics V. Ringer T. Kery A. Bonn GK. ...

https://en.wikipedia.org/wiki/Heartsease

... therapeutics. 123 (3): 386-400. doi:10.1016/j.pharmthera.2009.05.005. PMID 19486912.. ...

https://en.wikipedia.org/wiki/Carbon_monoxide

"AstraZeneca - AstraZeneca to acquire Pearl Therapeutics to strengthen respiratory portfolio". astrazeneca.com.. ... In February 2007, AstraZeneca agreed to buy Arrow Therapeutics, a company focused on the discovery and development of anti- ... The company's Medimmune arm also launched collaborative clinical trials with Juno Therapeutics, investigating combination ... AstraZeneca agrees to buy Arrow Therapeutics for $150 mln Marketwatch, 1 February 2007 ...

https://en.wikipedia.org/wiki/AstraZeneca

Therapeutics. 19 (3): 367-74. doi:10.1111/j.1365-2036.2004.01742.x. PMID 14984384.. ... Therapeutics. 14 (5): 639-50. doi:10.1046/j.1365-2036.2000.00723.x. PMID 10792129.. ...

https://en.wikipedia.org/wiki/Acetylsalicylic_acid

Lineage Therapeutics. Jun 14, 2013 Press Release: Lineage Therapeutics Markets Authorized Generic Epinephrine Auto-Injector ... "Therapeutics Initiative. 23 May 2019. Retrieved 24 July 2019.. *^ "Small children prioritised under emergency protocol to ... In June 2013, Amedra relaunched Adrenaclick.[62] and at the same time, Lineage Therapeutics launched its authorized generic ... And Lineage Therapeutics Inc. Archived 2016-08-27 at the Wayback Machine ...

https://en.wikipedia.org/wiki/Epi-pen

Clinical Therapeutics. 22 (2): 209-21. doi:10.1016/S0149-2918(00)88479-9. PMID 10743980.. ...

https://en.wikipedia.org/wiki/N-Acetylcysteine

... rising number of smoking people in the globe stimulate the growth of gingivitis diagnostics and therapeutics market ... Gingivitis Diagnostics and Therapeutics Market is anticipated to foresee tremendous growth rate in near future; ... Global Gingivitis Diagnostics and Therapeutics Market: Snapshot. The global market for gingivitis diagnostics and therapeutics ... Gingivitis Diagnostics And Therapeutics Market Size, Share, Growth, Sales, Trade, Shipment, Export Value And Volume With Sales ...

https://www.tmrresearch.com/gingivitis-diagnostics-therapeutics-market-

Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments ... Hereditary Angioedema (HAE) Therapeutics. Hereditary Angioedema (HAE) Therapeutics - Pipeline Analysis 2017, Clinical Trials & ... Some of the key players developing drugs for the treatment of HAE therapeutics include Shire plc, BioCryst Pharmaceuticals, Inc ... As of November 2017, the HAE therapeutics pipeline comprises of 20 drug candidates in different stages of development. ...

https://www.psmarketresearch.com/market-analysis/hereditary-angioedema-therapeutics-pipeline-analysis

Atriva Therapeutics lead candidate antiviral ATR-002 combines several advantages over existing therapies and could combat ... Atriva Therapeutics GmbH Rainer Lichtenberger, President and CEO, Atriva Therapeutics GmbH, Tübingen, Germany, Tel: +49 7071 ... Atriva Therapeutics: transforming antiviral therapies. By acting directly on human cell machinery, Atriva Therapeutics lead ... Atriva Therapeutics, a biopharmaceutical company based in Tübingen, Germany, is set to revolutionize the treatment of influenza ...

https://www.nature.com/articles/d43747-020-00936-1?error=cookies_not_supported&code=0b101bac-4e18-4e81-92a0-be47c81692d9

... therapeutics and vaccines, an entirely new drug technology that directs the bodys cells to produce intracellular or secreted ...

http://www.sciencemag.org/employer-profile/moderna-therapeutics

In June 2006, the Company (i) changed its name to Opexa Therapeutics, Inc. from PharmaFrontiers Corp. and (ii) effected a one- ... Exhibit 3.1 Articles of Amendment and Restatement of the Articles of Incorporation of Opexa Therapeutics, Inc. (1) ... Pursuant to 18 U.S.C. Section 1350, the undersigned Officer of Opexa Therapeutics, Inc. (the "Company"), hereby certifies, to ... Pursuant to 18 U.S.C. Section 1350, the undersigned Officer of Opexa Therapeutics, Inc. (the "Company"), hereby certifies, to ...

https://www.sec.gov/Archives/edgar/data/1069308/000115752306008508/a5210533.htm

Gluten Free Therapeutics (http://www.glutenfreetherapeutics.com) announce the launch of Celi•Vites, a line of ... About Gluten Free Therapeutics/Celi•Vites Maine-based Gluten Free Therapeutics is the parent company of Celi•Vites, a line of ... she serves as the vice president of research and development at Gluten Free Therapeutics. ... Gluten Free Therapeutics (http://www.glutenfreetherapeutics.com) announce the launch of Celi•Vites, a line of scientifically ...

http://www.prweb.com/releases/2013/12/prweb11399952.htm

Shares of Acorda Therapeutics Inc. jumped Monday after the company said that its drug Ampyra helped stroke patients recover ... NEW YORK (AP) -- Shares of Acorda Therapeutics Inc. jumped Monday after the company said that its drug Ampyra helped stroke ...

https://www.yahoo.com/news/acorda-therapeutics-rises-ampyra-study-154616998.html?ref=gs

Vaidya K.S., Sabbisetti V.S., Silveira A. (2014) Prostate Cancer Experimental Therapeutics. In: Schwab M. (eds) Encyclopedia of ...

https://link.springer.com/referenceworkentry/10.1007/978-3-642-27841-9_6773-2

We use cookies to improve our service and to tailor our content and advertising to you. More info Close You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our cookies policy Close ...

https://www.bmj.com/specialties/drugs-and-therapeutics

of Pharmacology and Therapeutics. *Read more about Online Seminar - A Tale of Two Drug Development Programs: A TGF-beta trap ... Pharmacology & Therapeutics. McIntyre Medical Building. 3655 Prom. Sir William Osler. Room 1325. Montreal, Quebec H3G 1Y6. Tel ...

https://www.mcgill.ca/pharma/category/audience/staff

A one-week module of the MSc in Experimental Therapeutics. Offered by the Department of Oncology and the Department for ... Biological Therapeutics. A one-week module of the MSc in Experimental Therapeutics. Offered by the Department of Oncology and ... The Biological Therapeutics course will provide students with the opportunity to learn more about and discuss the following ...

http://www.ox.ac.uk/research/innovation-and-partnership/news-and-events/2015-10-05-biological-therapeutics

Intellia Therapeutics ended March with $297 million in cash, which ranked behind both Editas Medicine and CRISPR Therapeutics. ... CRISPR Therapeutics (NASDAQ: CRSP), valued at $2.7 billion, was the first to advance a drug to clinical trials, and it has ... Intellia Therapeutics is behind its peers when it comes to advancing assets into clinical trials, but it all comes down to the ... Intellia Therapeutics, on the other hand, is targeting liver diseases with an in vivo approach. The organ requires a very ...

https://finance.yahoo.com/news/intellia-therapeutics-buy-164123421.html

Therapeutics at McGill University maintains several key resources for use by faculty and students for their research. Confocal ... Pharmacology & Therapeutics. McIntyre Medical Building. 3655 Prom. Sir William Osler. Room 1325. Montreal, Quebec H3G 1Y6. Tel ... The Department of Pharmacology & Therapeutics at McGill University maintains several key resources for use by faculty and ...

https://www.mcgill.ca/pharma/core-facilities

... 17 - 19 September 2018, Reading, United Kingdom ...

http://www.rsc.org/events/detail/29464/qp-module-medicinal-chemistry-and-therapeutics/venue

Norovirus structures could help develop therapeutics to fight food-borne illness Noroviruses are a leading cause of food-borne ... Harnessing the power of skin microbiome to develop new therapeutics As scientific researchers continue to investigate the ... research team led by scientists at the University of Alabama at Birmingham has identified a potential target for therapeutics ... therapeutics) or support overall skin health (cosmetics). ...

https://www.news-medical.net/?tag=/therapeutics

Toxicology and Therapeutics at the University of Kansas Medical Center. Faculty in our department have diverse research ... Likewise, in Therapeutics, faculty members use metabolomics approaches to study herbal medicines ability to cause drug ... Pharmacology, Toxicology & Therapeutics. Pharmacology and Toxicology together form a discipline that examines the interactions ... Faculty members in the Department of Pharmacology, Toxicology & Therapeutics at KUMC have diverse research interests. These ...

http://www.kumc.edu/school-of-medicine/pharmacology-toxicology-and-therapeutics.html

Focuses on cutting-edge research and applications to find and examine new approaches using nucleic acids in therapeutics ... Nucleic Acid Therapeutics. • formerly Oligonucleotides. Co-Editors-in-Chief: Bruce A. Sullenger, PhD and Annemieke Aartsma-Rus ... Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational ... Nucleic Acid Therapeutics is a rapid-publication Journal, with peer review averaging 25 days from submission to first decision ...

http://www.liebertpub.com/overview/nucleic-acid-therapeutics-formerly-oligonucleotides/601/

ACOR, Acorda Therapeutics, Biopharmaceutical, Biotie Therapies, BITI, M&A Acorda Therapeutics To Acquire Biotie Therapies To ... ACOR, Acorda Therapeutics, AMPYRA, dalfampridine, News, par pharmaceutical Acorda Therapeutics Confirms It Entered Into A ... ACOR, Acorda Therapeutics, Biotechnology, Health Care, Piper Jaffray, Upgrades Piper Jaffray Upgrades Acorda Therapeutics To ... ACOR, Acorda Therapeutics, Biotechnology, Citigroup, Health Care, Analyst Ratings Citigroup Expects Acorda Therapeutics To Be ...

https://www.benzinga.com/topic/acorda-therapeutics

PRNewswire/ -- INTRODUCTION Peptide therapeutics, due to their numerous advantages such as high selectivity, stability, ... Rani Therapeutics, Tarsa Therapeutics and Zosano Pharma are also emerging and have one or multiple peptides in early stages of ... for the overall market of peptide therapeutics in metabolic disorders.. Chapter 6 focuses on peptide therapeutics that have ... It offers a high level view on the current scenario of the peptide therapeutics market for metabolic disorders and where it is ...

https://www.prnewswire.com/news-releases/peptide-therapeutics-in-metabolic-disorders-2016---2025-300364103.html

The Society for Brain Mapping and Therapeutics (SBMT) is a non-profit biomedical association (501c6) principally concerned with ... "Annual World Congress of Society for Brain Mapping and Therapeutics". volunteer.ucla.edu.. ... The Society for Brain Mapping and Therapeutics (SBMT) was founded in 2004 to break boundaries in healthcare. The society ... Many names were proposed including: International Society for Brain Mapping and Therapeutics (ISBMT) and Society for Brain ...

https://en.wikipedia.org/wiki/Society_for_Brain_Mapping_and_Therapeutics

9, 2015 /PRNewswire/ -- Adheron Therapeutics, a privately held biotechnology company based in Berkeley, California, United ... About Adheron Therapeutics. Adheron Therapeutics is a biotechnology company focused on leveraging pioneering technology that ... Adheron Therapeutics to be acquired by Roche Lead molecule, SDP051, is a Cadherin-11 inhibitor based on a pioneering cell ... Adheron Therapeutics completed a Phase 1 trial of SDP051, which assessed the safety and tolerability of the compound in healthy ...

https://www.prnewswire.com/news-releases/adheron-therapeutics-to-be-acquired-by-roche-300156996.html?$G1Ref

United Therapeutics notches win in fight over blocked generic rival. United Therapeutics Corp can continue to restrict how ... About United Therapeutics Corporation. United Therapeutics Corporation is a biotechnology company. The Company is focused on ... BRIEF-United Therapeutics Files Lawsuit Against Liquidia For Infringement Of Tyvaso Patents. * UNITED THERAPEUTICS CORP - FILES ... BRIEF-Liquidia Responds To United Therapeutics Corporation Lawsuit. * LIQUIDIA RESPONDS TO UNITED THERAPEUTICS CORPORATION ...

https://www.reuters.com/companies/UTHR.OQ

VistaGen Therapeutics Inc. financial and business news, updates, and information from The New York Times and other leading ... VistaGen Therapeutics Inc. financial and business news, updates, and information from The New York Times and other leading ... News about VistaGen Therapeutics Inc., including commentary and archival articles published in The New York Times. ...

https://www.nytimes.com/topic/company/vistagen-therapeutics-inc

BRIEF-Revance Therapeutics Files For Potential Mixed Shelf Offering ‍‍ * REVANCE THERAPEUTICS INC FILES FOR POTENTIAL MIXED ... BRIEF-Revance Therapeutics reports qtrly net loss per share attributable to common stockholders basic and diluted‍ $1.01 * ... BRIEF-Revance Therapeutics updates on phase 2 clinical trial results * Positive Belmont phase 2 trial results published in ... Revance Therapeutics Inc - ‍sakura 1 & 2 phase 3 pivotal trials on track to report topline results before year-end 2017 ...

https://in.reuters.com/finance/stocks/company-news/RVNC.OQ

FDA and University of Maryland CERSI Lecture on Zika Virus Vaccines and Therapeutics by Monica McArthur, MD, PhD, University of ... At the time of the lecture, there were no licensed vaccines or therapeutics against Zika virus; however, there were numerous ... The anti-Zika virus vaccine candidates in the pipeline as well as ongoing efforts to identify therapeutics effective against ...

https://www.fda.gov/science-research/advancing-regulatory-science/zika-virus-vaccines-and-therapeutics

Juno Therapeutics, Inc. today announced that it entered into a settlement agreement to resolve litigation with the Trustees of ... Juno Therapeutics, Inc. ("Juno") is building a fully integrated biopharmaceutical company focused on revolutionizing medicine ... SEATTLE, April 6, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO) today announced that it entered into a ...

https://www.cnbc.com/2015/04/06/globe-newswire-juno-therapeutics-announces-patent-litigation-settlement.html

Find the latest United Therapeutics Corporation (UTHR) stock forecast based on top analysts estimates, plus more investing and ... United Therapeutics is a biotechnology company focused on the development and commercialization of therapeutic products for ...

https://finance.yahoo.com/research/reports/ARGUS_3485_AnalystReport_1591660800000/

Addex Therapeutics announced today the publication of its Annual Report 2013 in accordance with the notice given in the press ... About Addex Therapeutics. Addex Therapeutics (www.addextherapeutics.com) is a discovery and development stage company focused ... Addex Therapeutics. +41 22 884 15 61. [email protected] Disclaimer: The foregoing release may contain forward-looking ... Addex Therapeutics is providing the information in this press release as of this date and does not undertake any obligation to ...

https://www.cnbc.com/2014/05/30/globe-newswire-addex-therapeutics-publishes-annual-reports-2013.html

Complement Therapeutics. Editors: Lambris, John D., Holers, V. Michael, Ricklin, Daniel (Eds.) ... The chapters in this book cover a wide range of topics related to the development of complement therapeutics, ranging from the ... Progress and Trends in Complement Therapeutics.- Inhibition of the serine proteases of the complement system.- The role of MASP ... Complement-targeted therapeutics in periodontitis.- Complement system activation in cardiac and skeletal muscle pathology: ...

https://www.springer.com/us/book/9781461441175?wt_mc=ThirdParty.SpringerLink.3.EPR653.About_eBook

LIVONIA, Mich., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), announces today that its Board of Directors has approved a workforce reduction in order to reduce costs and conserve cash resources. (globenewswire.com)

Shares of Acorda Therapeutics Inc (NASDAQ: ACOR) were trading lower by 2 percent early Friday, but have since recovered most of the losses. (benzinga.com)
Acorda Therapeutics Inc (NASDAQ: ACOR) accused one of its rivals, Par Pharmaceutical, of infringing patents related to its multiple sclerosis treatment drug called Ampyra (dalfampridine) back in September, 2015. (benzinga.com)
Acorda Therapeutics Inc (NASDAQ: ACOR), a biopharmaceutical company that develops therapies for neurological disorders, on Tuesday announced that it has acquired Biotie Therapies Oyj (ADR) (NASDAQ: BITI) for $25.60 per ADS. (benzinga.com)
Piper Jaffray has upgraded Acorda Therapeutics (NASDAQ: ACOR) from Underweight to Neutral and has raised the price target from $21 to $30. (benzinga.com)
Acorda Therapeutics, Inc. (NASDAQ: ACOR) reported a solid Q3 driven by strong sales and tight exp Controls, Citigroup reports. (benzinga.com)
This quarter, Acorda Therapeutics, Inc. (NASDAQ: ACOR) and Celgene Corporation (NASDAQ: CELG) are the leaders of the pack. (benzinga.com)
SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2021 financial results and provided a corporate update. (yahoo.com)
MONOVISC Revenue Increased 50% Year-over-Year BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 25, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today reported financial results for the third quar. (corporate-ir.net)
BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 23, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the appointment of Thomas M. Finnerty as its Chief Human Resources Officer. (corporate-ir.net)
BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 16, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that regulatory authorities in Australia granted approval to MONOVISC®, Anika's single injection viscosupplement for the treatment of pain associated with osteoarthritis of all synovial joints, including t. (corporate-ir.net)
BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 11, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2017 financial results after the close of the market on Wednesday, October 25, 2017 and to hold a conference call the next day, Thursday, October 26, 2017, at 9:00 a.m. (corporate-ir.net)
Deep international expertise to drive the Company's global expansion BEDFORD, Mass.--(BUSINESS WIRE)--Aug. 28, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs. (corporate-ir.net)
27, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the appointment of Joseph Darling, an orthopedic and medical device veteran with broad commercial experience, to the role. (corporate-ir.net)
26, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today reported financial results for the second quarter ended June 30. (corporate-ir.net)
Intercept Pharmaceuticals (NASDAQ: ICPT) and Viking Therapeutics (NASDAQ: VKTX) arguably sport two of the most promising experimental NASH therapies in their respective pipelines. (nasdaq.com)
CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced the appointment of Stephen Webster to its Board of Directors. (globenewswire.com)
Shares of Akebia Therapeutics (NASDAQ: AKBA)have jumped today, rising 17.8% as of 11:49 a.m. (foxbusiness.com)
PTC Therapeutics, Inc. , (NASDAQ: PTCT) today announced that it has entered into an agreement to acquire Agilis Biotherapeutics , Inc., a biotechnology company advancing an innovative gene therapy platform for rare monogenic diseases that affect the central nervous system (CNS). (biospace.com)
Proteon Therapeutics Craters on Missed Late-Stage Results (NASDAQ: PRTO) - 24/7 Wall St". 24/7 Wall St. Retrieved 2017-02-28. (wikipedia.org)

The Department of Pharmacology & Therapeutics at McGill University maintains several key resources for use by faculty and students for their research. (mcgill.ca)
Faculty members in the Department of Pharmacology, Toxicology & Therapeutics at KUMC have diverse research interests. (kumc.edu)
The Department of Pharmacology and Therapeutics is located in the Western Gateway Building and in the School of Pharmacy on the main campus. (ucc.ie)
To provide excellence in undergraduate and postgraduate teaching in Pharmacology, Toxicology, Clinical Pharmacology and Therapeutics. (ucc.ie)
Small Animal Pharmacology and Therapeutics, 2nd Edition helps you understand both the therapeutic uses of common pharmaceuticals and the pharmacology behind them, giving you all of the information you need to design and modify dosing regimens, identify factors that cause drugs to fail, and anticipate adverse drug reactions. (elsevier.com)
Journal of Ocular Pharmacology and Therapeutics publishes new treatment modalities and their impact on ocular tissues and the potential side effects, and newly diagnosed side effects, of any medication or treatment that is already in use in ophthalmic practice. (liebertpub.com)
Journal of Ocular Pharmacology and Therapeutics provides insight into research being conducted by both academic and industry labs focused on the biology and therapeutic side of ocular diseases. (liebertpub.com)
Journal of Ocular Pharmacology and Therapeutics is the only peer-reviewed journal that combines the fields of ophthalmology and pharmacology to enable optimal treatment and prevention of ocular diseases and disorders. (liebertpub.com)
The Journal of Ocular Pharmacology and Therapeutics (JOPT) is a peer-reviewed journal published 10 times a year. (liebertpub.com)
Your submission to Journal of Ocular Pharmacology and Therapeutics (JOPT) provides you with robust tools and support to ensure maximum impact and readership for your work. (liebertpub.com)
Submitting your manuscript to Journal of Ocular Pharmacology and Therapeutics (JOPT ) delivers a comprehensive benefits program that ensures high-quality review of your research and maximum impact for your work. (liebertpub.com)
Journal of Ocular Pharmacology and Therapeutics (JOPT) carries a manuscript processing charge* of $75 USD upon submission of each new manuscript. (liebertpub.com)
Pharmacology & Therapeutics presents lucid, critical and authoritative reviews of currently important topics in pharmacology . (elsevier.com)
Founded in 1976, Pharmacology & Therapeutics continues. (elsevier.com)
Founded in 1976, Pharmacology & Therapeutics continues to be among the top 10 most cited journals in pharmacology. (elsevier.com)

As of November 2017, the HAE therapeutics pipeline comprises of 20 drug candidates in different stages of development. (psmarketresearch.com)
CAMBRIDGE, Mass. , May 16, 2017 /CNW/ -- Dragonfly Therapeutics, Inc. ('Dragonfly'), today announced that Dr. Ann Cheung will become its Head of Biology, directing key immuno-oncology functions for the development of its novel Natural Killer ('NK') cell-based therapies. (newswire.ca)
Intarcia Therapeutics said today that it raised $215 million in a new round of financing to back its ITCA 650 implantable drug pump, designed for treating Type II diabetes, which is slated to launch in late 2017. (massdevice.com)

Mr. Webster served as the Chief Financial Officer of Spark Therapeutics, a publicly traded gene therapy biotechnology company, from July 2014 until its acquisition by Roche for $4.3 billion in December 2019. (globenewswire.com)
SMi Group announces the 10th Annual RNA Therapeutics Conference in London on February 20th - 21st 2019 . (smi-online.co.uk)
Join us in February 2019, as SMi's RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to discuss the challenges for clinical translation of RNA-based therapeutics, with an emphasis on recent advances in delivery technologies , and present an overview of the applications of RNA-based drugs for modulation of gene and protein expression, and genome editing. (smi-online.co.uk)
The SMi Group is delighted to announce it's 19th Annual Pain Therapeutics conference which will be held in London on the 13th and 14th May 2019. (smi-online.co.uk)
In September 2019, Proteon Therapeutics merged with ArTara Therapeutics. (wikipedia.org)

GENEVA, May 30, 2014 (GLOBE NEWSWIRE) -- Addex Therapeutics (SIX: ADXN) announced today the publication of its Annual Report 2013 in accordance with the notice given in the press release of 30 April 2014. (cnbc.com)
DALLAS, Texas, June 16, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies for prevention and treatment of kidney diseases, today reported the publication of results from a Phase 1 study evaluating the safety and efficacy of RBT-6 (stannous protoporphyrin) for assessing select antioxidant defenses in patients with CKD. (globenewswire.com)

NEW YORK (AP) -- Shares of Acorda Therapeutics Inc. jumped Monday after the company said that its drug Ampyra helped stroke patients recover their ability to walk in a mid-stage clinical trial. (yahoo.com)
Reuters) - Acorda Therapeutics Inc said on Monday it would stop developing its Parkinson's disease drug, tozadenant, less than a week after the company reported deaths in key studies testing the treatment. (reuters.com)
Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders. (oracle.com)

A one-week module of the MSc in Experimental Therapeutics. (ox.ac.uk)
Diversity is no stranger to the Experimental Therapeutics department and the broad range of research interests that motivate our faculty. (mdanderson.org)

We are very excited about this acquisition, as it is an important step towards the development of breakthrough medicines in the area of inflammation and fibrosis,' said Hari Kumar , Chief Executive Officer of Adheron Therapeutics. (prnewswire.com)
Our organization is fully aligned and executing on the priorities that will enable us to develop our pipeline and ultimately deliver new treatments to people living with rare diseases," said Eric Dube, Ph.D., chief executive officer of Travere Therapeutics. (yahoo.com)
His distinguished track record of leading companies through periods of growth will prove invaluable at this moment in time as we prepare to present clinical data for our two lead programs, TC-210 and TC-110, and advance a third mono TRuC-T cell therapy towards the clinic," said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR 2 Therapeutics. (globenewswire.com)
Kerrie was also the co-founder and chief operations officer for Arcion Therapeutics Inc. Previously, she was the founder, president and chief executive officer of Traxion Therapeutics, Inc., a biotech company focused on the development of new drugs to treat intractable pain. (smi-online.co.uk)
This expanded alliance with Shionogi further validates our platform and the potential for BPN14770 to provide a new treatment option for patients suffering from Alzheimer's disease," said Mark Gurney, Ph.D., Chairman and Chief Executive Officer of Tetra Therapeutics. (businesswire.com)
The addition of the gene therapy platform transforms PTC and aligns with our vision of being a leader in the treatment of rare disorders," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "We are impressed with the clinical results shown by the AADC program and are excited with the potential to quickly bring this therapy to patients. (biospace.com)

Nature selects Temprian Therapeutics as a finalist for their Spinoff Prize 2020, which celebrates early stage university spinoff companies. (prweb.com)

Anika Therapeutics Inc. (nasdaq.com)
Anika Therapeutics, Inc. is global medical technology company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration and wound healing. (cnn.com)
Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA. (cnn.com)

Some of the key players developing drugs for the treatment of HAE therapeutics include Shire plc, BioCryst Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (psmarketresearch.com)
Intellia Therapeutics and Regeneron Pharmaceuticals are still collecting toxicology data on NTLA-2001. (yahoo.com)
Proteon Therapeutics, Inc. is a developer of pharmaceuticals with offices in Waltham, Massachusetts and Kansas City, Missouri. (wikipedia.org)

Modern biological research and much of drug discovery is often driven by the search for new molecularly targeted therapeutics ( 1 - 3 ). (pnas.org)

United Therapeutics Corporation is a biotechnology company. (reuters.com)

BERKELEY, Calif. , Oct. 9, 2015 /PRNewswire/ -- Adheron Therapeutics, a privately held biotechnology company based in Berkeley, California , United States , announced today that it has agreed to be acquired by Roche. (prnewswire.com)

The 'Peptide Therapeutics in Metabolic Disorders, 2016-2025' report provides a comprehensive analysis of the current market landscape and future outlook of peptide therapeutics targeting metabolic disorders. (prnewswire.com)
The report provides sales forecast for the overall peptide therapeutics market targeting metabolic disorders for the period 2016 - 2025. (prnewswire.com)
Mr. Webster has served as a director of Nabriva Therapeutics AG (formerly Nabriva Therapeutics plc), a publicly traded biopharmaceutical company, since August 2016 and Viking Therapeutics, a publicly traded biopharmaceutical company, since May 2014. (globenewswire.com)

Insys Therapeutics makes a spray version of the. (businessinsider.com)
Insys Therapeutics makes a spray version of the powerful opiate fentanyl, which is many times stronger than morphine. (businessinsider.com)
You've probably never heard of Insys Therapeutics. (businessinsider.com)

By acting directly on human cell machinery, Atriva Therapeutics' lead candidate antiviral ATR-002 combines several advantages over existing therapies and could combat respiratory diseases such as influenza and COVID-19. (nature.com)
There is a dire need for a safe and efficacious therapy that avoids resistance, has a broader treatment window, and is suitable for high-risk groups," said Rainer Lichtenberger, co-founder and CEO of Atriva Therapeutics. (nature.com)
Atriva Therapeutics, a biopharmaceutical company based in Tübingen, Germany, is set to revolutionize the treatment of influenza, COVID-19 and other potentially life-threatening respiratory diseases. (nature.com)

Intellia Therapeutics ended March with $297 million in cash, which ranked behind both Editas Medicine and CRISPR Therapeutics. (yahoo.com)
The lead drug candidate of CRISPR Therapeutics targets red blood cell disorders by editing stem cells found in bone marrow, but with an ex vivo approach. (yahoo.com)
CRISPR Therapeutics AG ( CRSP ) shares rose more than 5% during Tuesday's session after CTX001 received a Food and Drug Administration (FDA) Fast Track designation. (investopedia.com)
CRISPR Therapeutics launched a Phase I/II open label study in February, and the first patient for its sickle cell study should be infused by the middle of this year. (investopedia.com)
Earlier this week, Evercore ISI initiated coverage of CRISPR Therapeutics stock with an Outperform rating and a $46.00 price target . (investopedia.com)

Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck's Zetia lowered cholesterol level by 35 percent in a late-stage study, sending the company's shares up as much as 11 percent. (reuters.com)
Esperion Therapeutics, Inc. is a lipid management company. (reuters.com)
Esperion Therapeutics said on Wednesday its cholesterol drug was safe and effective in treating heart disease patients in a new late-stage study, weeks after data from an earlier trial raised concerns about the treatment's efficacy. (reuters.com)
Esperion Therapeutics Inc said on Tuesday its experimental oral drug met the main goal of reducing cholesterol by 30 percent in patients, who were already on another treatment to lower the risk of artery-clogging heart disease. (reuters.com)
Esperion Therapeutics Inc said on Tuesday a mid-stage study of its experimental oral drug met the main goal of reducing cholesterol. (reuters.com)
Esperion Therapeutics Inc said on Wednesday a late-stage trial of its experimental oral drug met the main goal of reducing cholesterol by 28 percent in patients suffering from, or at a high risk of, an artery-clogging heart disease. (reuters.com)

Adheron Therapeutics is a biotechnology company focused on leveraging pioneering technology that disrupts cell adhesion to treat a variety of diseases. (prnewswire.com)
United Therapeutics is a biotechnology company focused on the development and commercialization of therapeutic products for patients with cardiovascular conditions, cancer and infectious diseases. (yahoo.com)
UK-based biotechnology firm ILC Therapeutics is working alongside the University of Oxford to examine the use of Evasins - molecules derived from ticks - as a potential COVID-19 treatment option for patients whose lungs are badly damaged by the virus and face a critical juncture in recovery. (news-medical.net)
With nearly 30 years of biotechnology industry experience in raising capital, business development transactions and operations, Mr. Webster has played important roles as the Chief Financial Officer of Spark Therapeutics, Optimer Pharmacuticals and Adolor Corporation. (globenewswire.com)
Tetra Therapeutics is a clinical stage biotechnology company developing a portfolio of therapeutic products that will bring clarity of thought to people suffering from Fragile X syndrome, Alzheimer's disease, traumatic brain injury, and other brain disorders. (businesswire.com)
Renibus Therapeutics is a clinical stage biotechnology company developing novel therapies for kidney diseases. (globenewswire.com)

Potential areas of interest include, but are not limited to, engineered antibodies for cell targeting and imaging, antibodies involved in disease pathologies, and advances in antibody therapeutics. (aiche.org)
Boehringer Ingelheim and CDR-Life today announced they have entered into a collaboration and licensing agreement to research and develop antibody fragment-based therapeutics for geographic atrophy (GA). (news-medical.net)
Bicycle Therapeutics develops bicyclic peptides that provide antibody-like target specificity and high affinity. (genengnews.com)

[7] SBMT played a significant role in the formulation, planning and execution of Obama's BRAIN Initiative and in 2013 pioneered the G20+ World Brain Mapping & Therapeutic Initiative, which is aimed at creating a global consortium focusing on integration of nanotechnology, imaging, cellular/stem cell therapeutics, Information Technology (IT) and devices (this approach called NanoBioElectronics) in Brain Mapping. (wikipedia.org)

Likewise, in Therapeutics, faculty members use metabolomics approaches to study herbal medicines' ability to cause drug interactions with prescribed drugs. (kumc.edu)
Dragonfly Therapeutics harnesses its novel TriNKET technology to develop drugs that leverage the power of the innate immune system to provide breakthrough cancer treatments for patients. (newswire.ca)
The field of RNA therapeutics is rapidly expanding, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come. (smi-online.co.uk)
IRX Therapeutics' mission is to discover and commercialize drugs that stimulate a coordinated TH1-specific cellular immune response to treat human diseases. (xconomy.com)
Opsona Therapeutics was a drug development company specialising in the human immune system and new drugs and vaccines to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases. (wikipedia.org)

Adheron Therapeutics completed a Phase 1 trial of SDP051 , which assessed the safety and tolerability of the compound in healthy volunteers. (prnewswire.com)
This database provides a catalog of the therapeutics currently or previously tested as treatment for Alzheimer's disease and related disorders, focusing on those that have progressed to Phase 2 or beyond in U.S. clinical trials. (alzforum.org)
The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U.S. clinical trials. (alzforum.org)

Chronos Therapeutics , a private biotech company focused on ageing diseases, brain and nervous system disorders, announced that Dr. Huw Jones, CEO of Chronos, has been awarded Best CEO in the European Drug Discovery Industry by online and print magazine European CEO . (centerwatch.com)

Juno Therapeutics, Inc. ("Juno") is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. (cnbc.com)
Addex Therapeutics ( www.addextherapeutics.com ) is a discovery and development stage company focused on advancing innovative oral small molecules utilizing its pioneering allosteric modulation-based drug discovery platform. (cnbc.com)

Welcome to the Nature Communications Editors' Highlights webpage on therapeutics. (nature.com)

NORCROSS, Ga.--( BUSINESS WIRE )-- Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), today announced that it received approximately $1.65 million from the exercise of warrants that had an expiration date of March 1, 2013. (aol.com)

● FRONT RUNNER - the most promising therapeutics/vaccines based on clinical progress, favorable data or both. (genengnews.com)

the understanding of epigenetics is of importance for the development of innovative therapeutics including the potential pharmaceutical use of (pluripotent) stem cells. (cambridge.org)
Menlo Therapeutics Inc. is a clinical stage pharmaceutical company dedicated to the development of serlopitant, a once-daily oral NK-1 receptor antagonist, for the treatment of chronic pruritus and chronic cough. (medindia.net)

Peptide therapeutics, due to their numerous advantages such as high selectivity, stability, efficacy, safety, bioavailability and tolerability offer a number of benefits over other therapeutic classes. (prnewswire.com)
A majority of peptide therapeutics that we identified during our research are being developed for the treatment of diabetes, obesity, osteoporosis and acromegaly. (prnewswire.com)
In addition, there are several peptide therapeutics targeting other metabolic disorders such as Cushing's disease, hypoglycemia, cystic fibrosis and achondroplasia. (prnewswire.com)
The innovative technology platforms and delivery systems being offered to eliminate the challenges associated with the administration of peptide therapeutics. (prnewswire.com)
Recently approved and mid / late stage peptide therapeutics in terms of their history of development, available formulations, associated patents, key clinical trials and results. (prnewswire.com)
Intarcia Therapeutics and the California Institute for Biomedical Research said today that the 2 groups will collaborate to develop a peptide therapeutic for patients with type II diabetes and obesity. (massdevice.com)
Now, Bicycle Therapeutics has taken up the "peptide challenge" by rolling out an improved peptide expression platform. (genengnews.com)

The Journal delivers the latest discoveries in the pharmacokinetics and pharmacodynamics of therapeutics for the treatment of ophthalmic disorders. (liebertpub.com)

RNAi therapeutics start acting when a short piece of double-stranded RNA (somewhere between 20 and 25 or so nucleotides) enters a cell. (asbmb.org)

The Pharmacological Basis of Therapeutics is one. (google.com)

Intellia Therapeutics appears to be going all-in on LNPs as the foundation for its entire gene editing platform. (yahoo.com)
More Potent, Inexpensive Gene Silencing Agents Described in Nucleic Acid Therapeutics. (liebertpub.com)
Nucleic Acid Therapeutics is the leading journal in its field focusing on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. (liebertpub.com)

While the commercial availability of any new regenerative gingivitis treatments will mostly decide their potential of succeeding in the gingivitis diagnostics and therapeutics market, the way diagnosing technologies develop will also be a key determinant of the success of regenerative therapies. (tmrresearch.com)
The clinical therapeutics fall into four categories (antivirals, immunomodulators, supportive therapies, and neutralizing antibodies). (nih.gov)

The global market for gingivitis diagnostics and therapeutics is expected to witness growth at a significant rate in the next few years owing to factors such as the rising number of smokers, women of reproductive age, and obese people across the globe. (tmrresearch.com)
Thus, the increasing number of smokers across the world is providing a significant push to the global gingivitis diagnostics and therapeutics market. (tmrresearch.com)
This market intelligence report provides an in-depth analysis of the global gingivitis diagnostics and therapeutics market and its affiliated industries. (tmrresearch.com)
Changing lifestyles are leading to shift in dietary patterns that boosting the chances of gingivitis, thereby triggering the demand for gingivitis diagnostics and therapeutics. (tmrresearch.com)
However, the low awareness regarding the diagnostics and therapeutics of the disease along with the reluctance regarding the disease is hampering the growth of the market. (tmrresearch.com)
Nevertheless, the increasing government initiatives regarding educating common masses about oral health are likely to bode well for the growth of the global gingivitis diagnostics and therapeutics market in the near future. (tmrresearch.com)
Highly Multiplexed Proteomic Platform for Biomarker Discovery, Diagnostics and Therapeutics. (springer.com)
Experts in their field provide up-to-date information making the book very valuable for academia and biotech working in the field of diagnostics and therapeutics. (cambridge.org)

News about VistaGen Therapeutics Inc., including commentary and archival articles published in The New York Times. (nytimes.com)

This book comprises an integrated review of ocular therapeutics across all relevant fields. (springer.com)

Their reach will get a boost from a $64 million series C financing round that Pear announced at the top of the year-which will also help fuel the development and acquisition of digital therapeutics in other indications, as well as to help continue to gather the clinical evidence needed to drive adoption of the digital therapeutics. (fiercebiotech.com)
Based on distribution channel the schizophrenia and associated indications therapeutics market can be categorized into hospitals, clinics, retail pharmacies and rehabilitation centers. (mynewsdesk.com)
Geographically, the schizophrenia and associated indications therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. (mynewsdesk.com)
North America was observed to be the largest schizophrenia and associated indications therapeutics market due to increasing mental disorders. (mynewsdesk.com)

Aaron Royston , MD, of venBio will join the Menlo Therapeutics Board of Directors. (medindia.net)

Four months after the FDA rejected its diabetes drug-eluting implant, privately-held Intarcia Therapeutics has cut 60 employees and received a clinical hold for two of its ongoing marketing studies, according to reports. (massdevice.com)
Privately-held biopharma Intarcia Therapeutics revealed today that the FDA rejected its exenatide implant, ITCA 650, designed to treat Type II diabetes. (massdevice.com)

Imatinib revolutionized the treatment of Ph (+) CML and has emerged as a paradigm for the development of targeted therapy in cancer therapeutics. (springer.com)
The Therapeutics Innovation Core (TIC) - part of the Immunotherapy Integration Hub (IIH) - features Seattle Children's cancer immunotherapy program's research and development, process analytical development, pre-clinical development (PreClin) and correlative studies teams. (seattlechildrens.org)
Guided Therapeutics is also developing a non-invasive test for the early detection of esophageal cancer using the technology platform. (aol.com)
Here we review the mechanisms of lactate production and transport and highlight emerging evidence indicating that targeting lactate metabolism is a promising approach for cancer therapeutics. (jci.org)

Anatomy12

Organisms15

Diseases21

Chemicals and Drugs76

Analytical, Diagnostic and Therapeutic Techniques and Equipment58

Psychiatry and Psychology2

Phenomena and Processes46

Disciplines and Occupations21

Anthropology, Education, Sociology and Social Phenomena7

Technology, Industry, Agriculture22

Information Science7

Health Care10

R(1/180)

Issues in the measurement of satisfaction with treatment. (2/180)

Impact of electronic imaging on clinician behavior in the urgent care setting. (3/180)

Did Osler suffer from "paranoia antitherapeuticum baltimorensis"? A comparative content analysis of The Principles and Practice of Medicine and Harrison's Principles of Internal Medicine, 11th edition. (4/180)

Restricted natural language processing for case simulation tools. (5/180)

Detailed diagnoses and procedures, National Hospital Discharge Survey, 1997. (6/180)

A comparison of observational studies and randomized, controlled trials. (7/180)

Randomized, controlled trials, observational studies, and the hierarchy of research designs. (8/180)

Therapeutics

Pharmacy and Therapeutics Committee

Pharmacology, Clinical

Drug Delivery Systems

Neoplasms

Drug Design

Molecular Targeted Therapy

Antineoplastic Agents

Drug Discovery

Drug Evaluation, Preclinical

Cell Line, Tumor

Nanoparticles

Nanomedicine

Signal Transduction

Disease Models, Animal

Drug Carriers

Small Molecule Libraries

Clinical Trials as Topic

RNA, Small Interfering

Aptamers, Nucleotide

Drugs, Investigational

Protein Engineering

Models, Molecular

Antibodies, Monoclonal

Cell Proliferation

RNA Interference

Models, Biological

Drug Therapy

High-Throughput Screening Assays

Apoptosis

Xenograft Model Antitumor Assays

Biological Products

Individualized Medicine

Peptides

Protein Binding

Polymers

Pharmaceutical Preparations

Cell Line

Molecular Sequence Data

Immunotherapy

Biopharmaceutics

Inhibitory Concentration 50

Molecular Structure

Cell Survival

Enzyme Inhibitors

Nanotechnology

Oligonucleotides, Antisense

Convection

Protein Kinase Inhibitors

Central Nervous System Agents

Amino Acid Sequence

Mice, Nude

Structure-Activity Relationship

Mice, Inbred C57BL

Bioengineering

Cell-Penetrating Peptides

Translational Medical Research

Biotechnology

Drug Approval

Drug Resistance, Neoplasm

Ligands

Gene Expression Regulation, Neoplastic

Protein Structure, Tertiary

MicroRNAs

Drug Screening Assays, Antitumor

Formularies as Topic

Technology, Pharmaceutical

Peptide Library

Nucleic Acids

Mice, SCID

Biological Therapy

Mutation

Dose-Response Relationship, Drug

Antiviral Agents

Mice, Transgenic

Antibodies, Bispecific

Cells, Cultured

Alzheimer Disease

Therapies, Investigational

Mice, Inbred BALB C